Tanycytes, specialized glial cells lining the third ventricle of the hypothalamus, have traditionally been recognized for their roles in nutrient sensing and signaling to hypothalamic neurons. This new study highlights their capacity to secrete EVs in a diurnal rhythm, a process modulated significantly by the timing of daily feeding. By delving into the mechanistic underpinnings of this secretion, the investigators demonstrate that tanycyte-derived EVs act as crucial conveyors of molecular signals, finely tuning neuronal activities that regulate feeding behavior and energy homeostasis.

Central to this EV-mediated communication is the presence of the insulin precursor, prepro-insulin (ppIns), on the vesicle surfaces. The research team discovered that ppIns serves as a specificity determinant, facilitating the recognition and selective uptake of tanycytic EVs by insulin-receptor-positive neurons within the hypothalamus. This revelation underscores a sophisticated level of cellular cross-talk, whereby tanycytes target and modulate discrete neuronal populations through an insulin precursor-mediated mechanism, rather than classical hormone secretion pathways.

Beyond mere recognition and uptake, these EVs carry essential components of the mechanistic target of rapamycin complex (mTORC), a signaling hub integral to cellular metabolism and nutrient sensing. Notably, the study identifies Rictor, a defining protein of the mTORC2 subcomplex, within the EV cargo in a hypo-phosphorylated state. This molecular cargo is instrumental in augmenting neuronal signaling pathways that sustain feeding rhythmicity and metabolic resilience, emphasizing the functional relevance of EV content beyond protein presence to include specific post-translational modifications.

The experimental paradigm employed involved sophisticated inhibition of EV release from tanycytes, achieved through genetic manipulation techniques, which led to a marked disruption of feeding diurnality, impaired weight regulation, and compromised blood glucose control in animal models. This causative relationship firmly establishes tanycyte-derived EVs as fundamental effectors of metabolic rhythm maintenance and systemic energy balance, bridging the cellular and organismal scales of metabolic regulation.

Conversely, supplementation experiments with purified tanycytic EVs in vivo demonstrated compelling metabolic benefits, restoring feeding patterns and enhancing glucose homeostasis in models exhibiting metabolic dysfunction. This finding suggests that therapeutic modulation of EV release or administration could represent a novel strategy to rectify metabolic imbalances associated with disrupted circadian cycles, such as those seen in shift workers or metabolic syndrome patients.

From a molecular biology perspective, the precise sorting mechanisms enabling the selective inclusion of ppIns and mTORC components into tanycytic EVs remains an area of intense investigation. The study posits potential vesicular trafficking pathways and post-translational modification paradigms that guide cargo packaging, positioning tanycytes as active regulators of intra-hypothalamic signaling architecture.

Additionally, the study addresses how the diurnal secretion of EVs is entrained by feeding schedules, suggesting a feedback loop wherein metabolic status and nutrient availability dynamically influence tanycytic activity. This entrainment aligns with the broader circadian regulation observed in metabolic tissues, emphasizing tanycytes’ role as central integrators of environmental and physiological signals.

The implications for neuroendocrinology and metabolic medicine are broad and profound. By delineating a novel non-synaptic mode of neuronal regulation through EV-mediated delivery of metabolic signals, this research redefines our understanding of hypothalamic function. It posits that tanycytes, through precisely timed EV secretion, effectively “broadcast” metabolic status cues to neurons, coordinating feeding behavior with peripheral energy demands and internal clocks.

Moreover, the identification of ppIns on EV surfaces challenges classical notions of insulin signaling, which has primarily focused on circulating insulin originating from pancreatic beta cells. This paradigm shift suggests that hypothalamic insulin precursor-mediated signaling might operate synergistically or independently to fine-tune energy balance, opening new investigative pathways into insulin’s central roles.

The presence of Rictor in a low-phosphorylation state within EVs also signals a sophisticated regulation of downstream mTOR signaling cascades once these vesicles are internalized by recipient neurons. The study highlights how this delivery modulates intracellular pathways affecting neuronal excitability, gene expression, and ultimately, behavioral outputs related to feeding.

This study’s findings hold particular significance given the rising global incidence of metabolic disorders, including obesity and type 2 diabetes, conditions often exacerbated by circadian misalignment and disrupted feeding schedules. Targeting tanycyte-EV pathways could, therefore, become a transformative approach in designing interventions aimed at restoring metabolic health through the reinstatement of natural feeding rhythms.

In summary, the elucidation of tanycyte-derived extracellular vesicles as central regulators of feeding diurnality through insulin precursor-mediated neuronal recognition and delivery of mTORC components represents a paradigm shift in the neurobiology of metabolism. By bridging endocrinology, circadian biology, and extracellular vesicle research, this study paves the way for innovative therapies targeting hypothalamic communication networks to combat metabolic dysfunction.

As science continues to unravel the complexities of intercellular communication in the central nervous system, this research underscores the necessity of investigating non-traditional signaling modalities, such as EV-mediated molecular transfer, to fully understand and address the multifaceted nature of metabolic control and its disorders. The therapeutic promise of harnessing tanycytic EVs signals a new frontier in metabolic medicine, blending molecular precision with neurophysiological sophistication.

Future research will likely explore the broader spectrum of cargo within tanycytic EVs, their regulatory pathways, and interactions with other cell types within the hypothalamic milieu. Understanding these dimensions promises to uncover additional targets and mechanisms by which hypothalamic networks maintain energy homeostasis and adapt to metabolic challenges imposed by lifestyle and environmental factors.

In conclusion, this landmark study not only deepens our comprehension of hypothalamic regulation of metabolism but also presents tantalizing vistas for developing EV-based therapies aimed at synchronizing neural and metabolic rhythms. Its impact is poised to ripple across neurobiology, endocrinology, and clinical therapeutics, heralding a new era of precision intervention in metabolic health.

Subject of Research: The study focuses on the role of extracellular vesicles secreted by Sox2-positive tanycytes in the mediobasal hypothalamus in regulating feeding behavior and metabolic homeostasis through insulin precursor-mediated neuronal recognition and mTORC component delivery.

Article Title: Metabolic regulation by tanycyte-derived extracellular vesicles through insulin precursor-mediated neuronal recognition and mTORC component delivery.

Article References:
Choi, Y., Kim, M.W., Go, G. et al. Metabolic regulation by tanycyte-derived extracellular vesicles through insulin precursor-mediated neuronal recognition and mTORC component delivery. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01474-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01474-3

Central to this discovery is the vagus nerve, a major conduit of bidirectional signaling along the brain-liver axis. Typically, this nerve orchestrates metabolic homeostasis by modulating liver function according to brain signals. However, in the presence of cancer-induced systemic inflammation, the vagus nerve’s regulatory activity becomes severely dysregulated. This dysregulation precipitates profound metabolic disturbances in the liver, which are implicated in the progression of cachexia. The research team has effectively demonstrated that this disturbed neural communication is one of the primary drivers of the severe metabolic decline observed in cachexia patients.

The implications of these findings are transformative. In their landmark study, published in the prestigious journal Cell, Dr. Naama Darzi alongside Prof. Ayelet Erez from the Weizmann Institute and Dr. Aliesha Garrett from MD Anderson, employed targeted vagal blockade to intervene in this pathological neuro-liver signaling. Remarkably, their experiments using murine cancer models showed that selective inhibition of the right vagus nerve significantly hindered the development of cachexia. This blockage improved the animals’ metabolic profiles, increased their responsiveness to chemotherapy, and crucially enhanced survival rates, indicating a multi-dimensional therapeutic potential.

What makes this approach particularly promising is its basis in technologies already approved for clinical use, including non-invasive vagal nerve stimulation techniques. This translates to a highly feasible and near-term application in clinical oncology settings, setting a precedent for rapid translation from bench to bedside. The ease of application of this neural modulation therapy could ultimately revolutionize the management of cachexia, which presently lacks effective treatment options and is often a neglected aspect of cancer care.

The prevalence of cachexia varies by cancer type, reaching alarmingly high levels—up to 85%—among patients with pancreatic and lung cancers. In such cases, cachexia significantly shortens survival and diminishes quality of life. The new findings emphasize the critical importance of understanding brain-body communication pathways in the pathogenesis of metabolic disorders associated with cancer, breaking the traditional focus solely on peripheral metabolic abnormalities. This paradigm shift opens strategic avenues for targeted neuro-metabolic interventions.

Metabolic dysregulation in cachexia is complex and multifaceted, involving systemic inflammation, altered energy expenditure, and disrupted nutrient metabolism. The vagus nerve’s role as a mediator of liver function has thus emerged as a novel and highly specific therapeutic target. Blocking this signaling pathway appears to protect liver metabolism from the harmful cascade initiated by cancer-associated inflammatory processes. Through this neural intervention, the systemic catabolic state driving muscle wasting and adipose tissue loss can potentially be mitigated, addressing the syndrome’s root cause rather than merely its symptoms.

The study’s methodology involved sophisticated neurophysiological techniques to achieve selective vagal blockade, paired with detailed metabolic assessments and survival analyses in cancer-afflicted mice. These technical advancements enabled the identification of causal pathways linking brain inflammation, vagus nerve activity, and hepatic metabolic disruption. By combining non-invasive neural modulation with chemotherapeutic strategies, the researchers demonstrated synergistic benefits, underscoring the importance of integrated treatment protocols to combat cachexia.

Beyond therapeutic potential, the research contributes profound conceptual insights into the overarching role of neuroimmune crosstalk in metabolic disease. It challenges established notions by implicating central nervous system pathways as active contributors to peripheral metabolic pathology in cancer. This insight may have broader relevance for other chronic conditions characterized by inflammation-induced metabolic derangements, suggesting that neural modulation could emerge as a versatile clinical tool across various disciplines.

The significance of this research extends to ongoing clinical trials testing vagal nerve modulation in human patients. Given that technologies such as vagus nerve stimulation devices have regulatory approval for other indications, their repurposing to target cachexia could accelerate translational timelines dramatically. The prospect of applying such neural interventions to improve not only quality of life but also survival in cancer patients reframes cachexia from a fatal complication to a manageable syndrome amenable to precision neuromodulatory therapies.

Prof. Ayelet Erez, the lead investigator and dean of the Miriam and Aaron Gutwirth Medical School, underscores the collaborative nature of this breakthrough. Supported by several funding organizations dedicated to cancer research and clinical innovation, her team exemplifies the power of interdisciplinary science merging neurobiology, immunology, and oncology. This synergy enabled the formulation and validation of this unprecedented hypothesis that brain-liver neural communication governs systemic metabolic stability in cancer.

These discoveries herald a new horizon in cancer treatment paradigms where the nervous system’s role in cancer comorbidities is acknowledged and therapeutically exploited. By focusing on restoring physiological neural signaling rather than merely targeting tumor cells or metabolic endpoints, this research aligns with emerging trends in holistic precision medicine. Ultimately, the approach holds promise to stave off the metabolic collapse associated with cachexia, thereby improving therapeutic outcomes and survival probabilities in cancer patients faced with this deadly syndrome.

In summary, the unraveling of vagal nerve dysregulation in cancer-associated cachexia represents a major scientific leap with tangible clinical prospects. As research progresses, further delineation of the molecular and electrophysiological mechanisms involved will refine these neuromodulatory techniques. Meanwhile, the effectiveness of targeted vagal blockade in preclinical models offers a compelling rationale for expanded clinical trials. Patients afflicted by cancers with high cachexia incidence stand on the cusp of benefiting from innovative interventions that may dramatically alter the natural course of disease and improve their quality of life.

Subject of Research: Cancer-associated cachexia and brain-liver neuro-metabolic communication
Article Title: Vagal blockade of the brain-liver axis deters cancer-associated cachexia
News Publication Date: 7-Aug-2025
Web References: http://dx.doi.org/10.1016/j.cell.2025.07.016
References: Published in Cell, DOI: 10.1016/j.cell.2025.07.016
Keywords: Cancer treatments, Cachexia, Cell biology, Cancer research